资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled， double-blind dose-escalation trial.

Lancet Respir Med. 2019;

TamerisMichele，MearnsHelen，Penn-NicholsonAdam，GreggYolande，BilekNicole，MabweSimbarashe，GeldenhuysHennie，ShenjeJustin，LuabeyaAngelique Kany Kany，MurilloIngrid，DoceJuana，AguiloNacho，MarinovaDessislava，PuentesEugenia，RodríguezEsteban，Gonzalo-AsensioJesús，FritzellBernard，TholeJelle，MartinCarlos，ScribaThomas J，HatherillM

Products/Services Used	Details	Operation
Peptide Synthesis	Primary immunogenicity outcomes were antigen- specific CD4 and CD8 T-cell responses on days 7, 28, 70, 180 and 360, which were measured by whole blood intracellular cytokine staining as previously described,33 after stimulation with MTBVAC (1 × 10⁶ CFU per mL blood), a pool of 122 peptides of immunodominant M tuberculosis epitopes (MegaPool [Genscript, Piscataway, NJ, USA];34 1 µg/mL per peptide), phytohaemagglutinin (R30852801 [Thermo Fisher Scientific, Waltham MA, USA; 5 µg/mL), or media (unstimulated control).	Get A Quote

摘要

Infants are a key target population for new tuberculosis vaccines. We assessed the safety and immunogenicity of the live-attenuated Mycobacterium tuberculosis vaccine candidate MTBVAC in adults and infants in a region where transmission of tuberculosis is very high.